| Revision as of 08:04, 3 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject← Previous edit |
Latest revision as of 19:39, 4 February 2024 edit undoVastV0idInSpace0 (talk | contribs)Extended confirmed users2,408 edits Fixed spacing between stub template and category templatesTag: 2017 wikitext editor |
| (24 intermediate revisions by 19 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
|
{{cs1 config|name-list-style=vanc}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
| ⚫ |
| verifiedrevid = 424784867 |
|
|
|
| Watchedfields = changed |
|
⚫ |
| verifiedrevid = 477227464 |
|
| IUPAC_name = 8a-phenyldecahydroquinoline |
|
| IUPAC_name = 8a-phenyldecahydroquinoline |
|
| image = Phenyldecahydroquinoline.svg |
|
| image = Phenyldecahydroquinoline.svg |
| Line 15: |
Line 19: |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number = 131556-11-1 |
|
| CAS_number = 131556-11-1 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 8GBT78N4EC |
|
| PubChem = 131397 |
|
| PubChem = 131397 |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| Line 22: |
Line 29: |
|
<!--Chemical data--> |
|
<!--Chemical data--> |
|
| C=15 | H=21 | N=1 |
|
| C=15 | H=21 | N=1 |
|
|
| smiles = C1(23CCCC2CCCN3)=CC=CC=C1 |
|
| molecular_weight = 215.3339 g/mol |
|
|
| smiles = c1ccccc1C32NCCCC2CCCC3 |
|
|
| InChI = 1/C15H21N/c1-2-7-13(8-3-1)15-11-5-4-9-14(15)10-6-12-16-15/h1-3,7-8,14,16H,4-6,9-12H2 |
|
|
| InChIKey = QEXADSRMRUUCQJ-UHFFFAOYAG |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C15H21N/c1-2-7-13(8-3-1)15-11-5-4-9-14(15)10-6-12-16-15/h1-3,7-8,14,16H,4-6,9-12H2 |
|
| StdInChI = 1S/C15H21N/c1-2-7-13(8-3-1)15-11-5-4-9-14(15)10-6-12-16-15/h1-3,7-8,14,16H,4-6,9-12H2 |
| Line 32: |
Line 36: |
|
}} |
|
}} |
|
|
|
|
|
'''8a-Phenyldecahydroquinoline''' ('''8A-PDHQ''') is a high affinity ]. It is a structural analog of ] with slightly lower binding affinity than the parent compound. (-)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-MK-801.<ref>{{cite journal|author=Chen C, Kozikowski AP, Wood PL, Reynolds IJ, Ball RG, Pang YP |title=Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency |journal=J Med Chem |year=1992| volume=35 |issue=9|pmid=1315871|pages=1634–8|doi=10.1021/jm00087a020}}</ref><ref>{{cite journal| author=Elhallaoui M, Laguerre M, Carpy A, Ouazzani FC |title=Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode |journal=J Mol Model |year=2002 |volume= 8 |issue=2| pmid=12032600 |pages=65–72| doi=10.1007/s00894-001-0067-4}}</ref> |
|
'''8a-Phenyldecahydroquinoline''' ('''8A-PDHQ''') is a high affinity ] developed by a team at Parke Davis in the 1950s.<ref>US Patent 3035059</ref> It is a structural analog of ] with slightly lower binding affinity than the parent compound. (−)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-].<ref>{{cite journal | vauthors = Chen C, Kozikowski AP, Wood PL, Reynolds IJ, Ball RG, Pang YP | title = Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency | journal = Journal of Medicinal Chemistry | volume = 35 | issue = 9 | pages = 1634–8 | date = May 1992 | pmid = 1315871 | doi = 10.1021/jm00087a020 }}</ref><ref>{{cite journal | vauthors = Elhallaoui M, Laguerre M, Carpy A, Ouazzani FC | title = Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode | journal = Journal of Molecular Modeling | volume = 8 | issue = 2 | pages = 65–72 | date = February 2002 | pmid = 12032600 | doi = 10.1007/s00894-001-0067-4 | s2cid = 34882820 }}</ref> |
|
|
|
|
|
== References == |
|
== References == |
|
{{reflist}} |
|
{{reflist}} |
|
|
|
|
|
|
{{Hallucinogens}} |
|
|
{{Ionotropic glutamate receptor modulators}} |
|
|
|
|
|
⚫ |
{{DEFAULTSORT:Phenyldecahydroquinoline, 8a-}} |
|
|
|
|
|
|
] |
|
{{Dissociative_hallucinogens}} |
|
|
{{Glutamate_receptor_ligands}} |
|
|
|
|
| ⚫ |
{{DEFAULTSORT:Phenyldecahydroquinoline, 8a-}} |
|
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
|